96 results about "Lateral flow immunoassay" patented technology

Multiplexed lateral flow assays, related methods, and devices are disclosed which are capable of simultaneously detecting multiple analytes. The assays are preferably immunoassays and can be multiplexed spatially, spectrally, and both spatially and spectrally. Multiplexed assays are disclosed employing quantum dots for applications including the detection of human proteins and the monitoring of microorganisms relevant to water contamination. The invention is widely adaptable to a variety of analytes such as biowarfare agents, human clinical markers, and other substances.

Lateral flow assay devices and methods for detecting a first member of a specific binding pair in a sample which comprises a plurality of nonspecific binding pair members are adapted for two step determinations. In one embodiment, a two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location The two step method further comprises allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and is dried on the lateral flow matrix at a location upstream of the delivery of the filtered sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a location downstream of the first location. Further embodiments comprise additional lateral flow immunoassay devices and methods for identifying IgE antibodies in a sample.

The present invention is a device for conveniently collecting and storing liquid samples, as well as applying an aliquot of the sample to a test device, such as a lateral flow immunoassay. The present invention comprises an absorbent swab and a dropper container containing an expression means for expressing the collected sample from the swab. After the collected sample has been expressed into the reservoir of the device, the device is capped. The device can be inverted over a test device, the sides of the reservoir squeezed and an aliquot of the sample applied, in a drop-wise manner, to the sample application well of the test device. The present invention is particularly useful for collecting viscous samples, such as saliva or oral fluid, in a drug of abuse testing setting.

Devices and methods incorporate lysis agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters a lysis agent. The lysis agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the initially lysis agent is localized between the sample application zone and the conjugate zone. The lysis agent is preferably soluble or miscible in the sample transport liquid, and the lysis agent is solubilized and activated upon contact with the sample transport liquid. The sample transport liquid then contains both lysis agent in solution or suspension and sample components in suspension. Any lysis-susceptible components in a sample, then being exposed in suspension to the lysis agent, are themselves lysed in situ. The running buffer then carries the analyte, including any lysis-freed components, to the detection zone.

The present invention includes compositions, kits and methods useful for the detection of mastitis in an animal. These agents and methods are primarily directed to a method of detecting the presence of mastitis, including sub-clinical mastitis, in cows, involving incubating a sample of milk from the cow with an agent that binds to lactoferrin such as, e.g., a monoclonal antibody specific for lactoferrin, and then detecting bound lactoferrin. The invention includes lateral-flow immunoassay methods and devices for assessing the presence of lactoferrin in milk samples.

The present invention relates to devices, kits, instruments and methods for conducting lateral flow assays. A naturally hydrophilic membrane a fluorescent or luminescent label are used in the present devices, kits, instruments and methods. Preferably, a single naturally hydrophilic membrane and/or a fluorescent or luminescent particle label is used.

The present invention relates to a method for detecting an analyte in a sample, wherein the sample to be analyzed is applied to a chromatographic carrier. After separating from an interfering substance which may be present in the sample, the analyte of interest is detected on the carrier by means of an immunological assay. Further, a test strip for carrying out the method of the invention is provided. The invention further relates to a method for reducing interference in a method for detecting an analyte on a chromatographic carrier.

A lateral flow immunoassay contact chemical test device and method integrates sample collection, prescreen testing, and confirmation sample collecting and storing with a single device and a minimum of steps. While particularly advantageously used with an oral fluid sample absorbed directly from a person's mouth, (in which constant monitoring of a collection process is made possible), the test device may be used with any of a variety of sample fluids. Prescreen testing and confirmation testing are performed on a single sample. Prescreen testing is performed by a lateral flow assay. The sample collection pad is subsequently separated from the wicking path to prevent continued migration from, and backflow into the sample collection pad, so that the confirmation sample is preserved in the sample collection pad. A multitude of antigens can be detected with a single device.

A lateral flow immunoassay featuring encapsulated metal particles. The encapsulated particles may use SERS nanotags as the detection modality. The use of encapsulated particles as a detection modality, in particular encapsulated SERS tags increases the sensitivity of an LFI prepared for visual reading and introduces the ability to obtain substantially more sensitive qualitative results or quantitative results through the analysis of a SERS spectrum read from an LFI prepared in accordance with the present invention. The use of SERS as detection modality also enhances the ability of an LFI device to be used for a multiplexed test. Other aspects of the present invention include LFI devices specifically configured to test whole blood, a reader for the detection and interpretation of a multiplexed assay and the hardware and software components used to implement the reader.

A test apparatus that allows testing for the presence of both drugs of abuse and alcohol within a single device. In general, the apparatus of the present invention includes a lateral flow immunoassay screening for various drugs of abuse and a reactive pad including an enzyme as a test for alcohol. The two types of tests are contained within the same housing and these tests are performed using the same sample source from a subject being tested.

The present invention provides methods, kits, compositions, and devices for detecting Anti-Mullerian hormone (AMH) in whole blood samples. In certain embodiments, the methods, kits, compositions, and devices employ immunoassays that generate a colorimetric or fluorescent signal (e.g., using antibodies conjugated to gold nanoparticles or fluorescent particles) where the signal generated is proportional to the approximate concentration of AMH in a whole blood sample. In particular embodiments, the present invention provides quantitative or semi-quantitative lateral flow immunoassay devices and kits for detecting AMH at home (e.g., in order for women to estimate their ovarian age or diagnose polycystic ovarian syndrome).

Antibodies having specific binding for the parent THC (Δ⁹-THC) and its major metabolites are provided which present a significant increase in sensitivity of immunoassays such as lateral flow immunoassays and ELISA for THC. The present invention also provides a rabbit hybridoma producing the antibody as a monoclonal antibody, a recombinant antibody, further molecularly engineered recombinant antibodies against parent Δ⁹-THC and its metabolites and cell lines producing the recombinant antibodies. The invention also provides applications of the antibody in immunoassays, particularly lateral flow immunoassays, specifically applications in detecting THC in body fluids, particularly saliva, and kits for determining the presence of THC.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

Disclosed is a test device for determining the presence or integrity of a biologic comprising a sample pad for receiving the biologic, a conjugate pad, and a test membrane comprising at least one test line comprising an immobilized mimetope, and methods of using the same.

The present invention includes compositions, kits, and methods useful for the detection of bacteria. These agents and methods are primarily directed to a method of detecting the presence of bacteria in a sample, involving incubating the sample with an agent that binds to bacteria, such as, e.g., an agent specific for peptidoglycan or a component thereof, and then detecting bound bacteria. The invention includes lateral-flow immunoassay methods and devices for assessing the total bacterial load in a liquid sample.

A lateral flow immunoassay system is provided that includes a housing having a base portion forming a first chamber therein and a body portion formed with three openings in fluid communication with the first chamber, a vial containing a buffer agent, and a sample collector for introducing a sample fluid into the first chamber via the second opening. The vial is mounted to the housing such that a dispensing side extends into the first opening for dispensing the buffer agent therefrom into the first chamber. The housing allows the buffer agent and sample fluid to be mixed within a reaction well formed within the first chamber to form a test sample mixture. The body portion is configured to receive a receiving end of an elongated holder in the third opening and allow a test strip secured in the holder to be brought into communication with the text sample mixture.

An immunochemical sampling device, kits including the sampling device, processes for production of the sampling device, and methods for use of the sampling device in lateral flow immunoassays. The sampling device comprises a solid support that is partially wrapped in a porous carrier, then covered in a hydrophobic cover. At its distal end, the porous carrier comprises a labeled binding reagent that is retained in the solid support until released into controlled flow with the liquid sample when the sampling device is brought into contact with a test strip.

The invention relates to a magnetic lateral flow immunoassay (LFIA) for a rapid detection of Tetrodotoxin (TTX) and a preparation method of a detection test strip, belonging to the technical field of TTX detection. The magnetic LFIA for the rapid detection of TTX is characterized in that: a sample pad, a combination pad labeled by magnetic beads and modified by anti-TTX specific rat monoclonal antibody, a chromatography membrane pre-coated with a detection line T of TTX-BSA and a control line C of IgG, a water absorbent pad are successively pasted on a base plate staggeredly by the distance between adjacent part being 1 mm, then a transparent plastic sealing membrane is coated on the top layer to form a magnetic LFIA test strip for the rapid detection of TTX; immunomagnetic beads are captured by chromatography, the rapid qualitative detection of TTX is realized according to the formed 1-2 macroscopic color developing strips after sample chromatography; the prepared magnetic LFIA test strip through a magnetism analyzer is detected, and the quantitative determination of TTX can be realized according to the detection values of the formed magnetic signal of the detection line and control line after sample chromatography.

A method of measuring the amount of TNF-related apoptosis-inducing ligand (TRAIL) polypeptide in a fluid sample of a subject in need thereof is disclosed. The method uses a lateral flow immunoassay (LFI) device.

Differing from conventional lateral flow immunoassay test strips, the present invention provides an immunoassay kit comprising a release strip and a reaction strip. When using this immunoassay kit to complete a competitive-type immunochromatographic test or a sandwich-type immunochromatographic test for a test sample, it needs to firstly put the release strip into the test sample for releasing a specific antibody (or antigen) conjugating with a marker into the test sample, so as to make the first antibody connect to a target object in the test sample; after that, the reaction strip is eventually put into the test sample after the release strip is removed out of the test sample. Therefore, the qualitative analysis result of the competitive/sandwich-type immunochromatographic test can be easily obtained by determining whether the test line shows the color reaction or not.

The present invention provides a method and system for performing analyte analysis with improved reliability of test results through use of quality assurance labels for accuracy and robust results.